HCM
Hutchmed
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
HCM Profile
Hutchmed (China) Limited
A developer of drugs for the treatment of oncology and immunological diseases for global market
Pharmaceutical
12/18/2000
03/17/2016
NASDAQ Stock Exchange
1,811
12-31
Depository Receipts (Ordinary Shares)
48th Floor, heung Kong Center, 2 Queen’s Road Central, Hong Kong
The company is the holding company of a biopharmaceutical group with main business in China, the United States and Europe. It focuses on the research, development, production and marketing of pharmaceuticals.
Hutchison Medicine (China) Co., Ltd. was incorporated in the Cayman Islands on December 18, 2000. The company is a global biomedical company in the commercialization stage, focusing on the discovery, development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immune diseases. Founded in 2000, according to Frost & Sullivan, the company was one of the first companies in China to build its own drug discovery engine with the goal of creating innovative therapies for the global market. With the progress of these innovations, the Company has increased its extensive clinical and regulatory, production and commercial operations and, as of the Latest Practicable Date, has developed into a fully integrated biomedical company with over 1,300 employees. As a result, the company has been able to retain full operational control of innovative drugs to fully realize its economic value in the two key markets of China and the United States, which account for nearly 60% of the global pharmaceutical market in 2020.